Systemic sclerosis (scleroderma) trials in Poland

In Poland 11 Also abroad 213

11 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Ossy, Warsaw
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 3Not yet taking people in Poland
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Beneﬁted from Continued Treatment.
Where
Bydgoszcz, Cracow, Katowice, Kielce, Ozarowice, Warsaw
People
340 worldwide
Run by
AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00
Phase 2Taking people
Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Where
Bydgoszcz, Nowa Sol, Warszawa
Age
18 years and over
People
36 worldwide
Run by
Mediar Therapeutics Inc.
See details and how to join2025-523288-39-00 · EU 2025-523288-39-00
Phase 3Taking people
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Where
Bialystok, Bydgoszcz, Cracow, Poznan, Warsaw
Age
18 years and over
People
448 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00
Phase 1Not yet taking people in Poland
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Bydgoszcz, Krakow, Poznan
Age
18 years and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
Phase 2Taking people
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Where
Bydgoszcz, Nowa Sól, Warsaw
Age
18 years and over
People
85 worldwide
Run by
Mediar Therapeutics
See details and how to joinNCT07287670
Phase 2Taking people
Platform Clinical Study for Conquering Scleroderma
Where
Bydgoszcz, Gdansk, Katowice, Poznan, Szczecin, Warsaw
Age
18 years and over
People
400 worldwide
Run by
Scleroderma Research Foundation, Inc.
See details and how to joinNCT06195072 · EU 2023-507129-40-00
Phase 2Taking people
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Where
Bydgoszcz, Lodz, Warsaw
Age
18 years and over
People
90 worldwide
Run by
Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00
Phase 1Taking people
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Where
Bytom, Gdansk, Gliwice, Lodz
Age
18 years and over
People
125 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00
Phase 3Taking people
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
Where
Warsaw
Age
18 years to 74 years
People
86
Run by
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
See details and how to joinNCT06297096
Phase 2Taking people
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
Where
Bialystok, Cracow, Malbork, Nowa Sol, Warsaw
Age
18 years and over
People
162 worldwide
Run by
Galderma R&D
See details and how to joinNCT07047690 · EU 2025-522294-11-00